Purple Financial Statements From 2010 to 2024
| KTOV Stock | ILA 7.20 0.20 2.70% |
Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
Purple |
Purple Biotech Company Return On Asset Analysis
Purple Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Purple Biotech Return On Asset | -0.0915 |
Most of Purple Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Purple Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Purple Biotech has a Return On Asset of -0.0915. This is 98.95% lower than that of the Pharmaceuticals sector and 99.61% lower than that of the Health Care industry. The return on asset for all Israel stocks is 34.64% lower than that of the firm.
Purple Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Purple Biotech competition to find correlations between indicators driving Purple Biotech's intrinsic value. More Info.Purple Biotech is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Purple Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Purple Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Purple Biotech Financial Statements
Purple Biotech stakeholders use historical fundamental indicators, such as Purple Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Purple Biotech's assets and liabilities are reflected in the revenues and expenses on Purple Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Purple Biotech. Please read more on our technical analysis and fundamental analysis pages.
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out the analysis of Purple Biotech Correlation against competitors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.